SEHK:2171Biotechs
Following Satri Cel Approval Is CARsgen Therapeutics Holdings (SEHK:2171) Fully Priced?
CARsgen Therapeutics Holdings (SEHK:2171) has drawn fresh investor attention after China’s National Medical Products Administration approved satricabtagene autoleucel, the first CAR T-cell therapy cleared globally for a solid tumor indication.
See our latest analysis for CARsgen Therapeutics Holdings.
The satri-cel approval came after a mixed period for CARsgen Therapeutics Holdings. The 1-day share price return was 7.68%, while the 30-day share price return was down 21.81% and the 1-year...